Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)

NCT03439514 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03439514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03439514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
April 17, 2018
Completion date
October 13, 2022
Enrollment
77 (actual)
Sites
107

Conditions

As the registry lists them; a condition with its own page is linked.

dilated cardiomyopathy, lamin a/c gene mutation